Lawrence D. Mayer - Publications, H-index & Citations

Lawrence D. Mayer

Princeton University

56H指数

202论文数

1.0W被引数

收录论文 35

发表时间

Improving combination cancer therapy: the CombiPlex® development platform

FUTURE ONCOLOGY

IF2.6

2018-01-24

OAAI

Tolcher, Anthony W.; Mayer, Lawrence D.

CPX-351 works synergistically in combination with FLT3 inhibitors against AML with FLT3-ITD

CANCER RESEARCH

IF16.6

2017-07-01

PREAI

Edwards, David K.; Javidi-Sharifi, Nathalie; Rofelty, Angela; Gordon, Max; Roth-Carter, Riley; Tardi, Paul; Mayer, Lawrence; Tyner, Jeffrey W.

CPX-351 cytotoxicity against fresh AML blasts is increased for FLT3-ITD+ cells and correlates with drug uptake and clinical outcomes

CANCER RESEARCH

IF16.6

2016-07-15

PREAI

Gordon, Max; Tardi, Paul; Mayer, Lawrence D.; Tyner, Jeffrey

Detection of Ara-CTP following exposure to CPX-351 and potentiation of action by fludarabine in leukemia cell lines using a bioluminescent bacterial biosensor

CANCER RESEARCH

IF16.6

2015-08-01

PREAI

Mayer, Lawrence D.; Anderson, Elizabeth; Bone, Heather; Robinson, Gareth; Reynolds, Garreth; Salisbury, Vyvyan

CPX-351 (cytarabine: daunorubicin liposome for injection) anti-leukemia activity is potentiated by Chk1 inhibition CPX-351 (阿糖胞苷: 注射用柔红霉素脂质体) 抗白血病活性被Chk1抑制增强

CANCER RESEARCH

IF16.6

2015-08-01

PREAI

Vincelette, Nicole D.; Karnitz, Larry M.; Karp, Judith E.; Smith, Douglas B.; Hess, Allan D.; Mayer, Lawrence D.; Kaufmann, Scott H.

Pharmacodynamic behavior of liposomal antisense oligonucleotides targeting Her-2/neu and vascular endothelial growth factor in an ascitic MDA435/LCC6 human breast cancer model

CANCER BIOLOGY & THERAPY

IF4.6

2014-10-27

OAAI

Waterhouse, DN; Dragowska, WH; Gelmon, KA; Mayer, LD; Bally, MB

Prediction of nanoparticle prodrug metabolism by pharmacokinetic modeling of biliary excretion

JOURNAL OF CONTROLLED RELEASE

IF11.5

2013-12-01

OAAI

Stern, Stephan T.; Zou, Peng; Skoczen, Sarah; Xie, Sherwin; Liboiron, Barry; Harasym, Troy; Tardi, Paul; Mayer, Lawrence D.; McNeil, Scott E.

Effects of block copolymer properties on nanocarrier protection from in vivo clearance

JOURNAL OF CONTROLLED RELEASE

IF11.5

2012-08-01

105

OAAI

D'Addio, Suzanne M.; Saad, Walid; Ansell, Steven M.; Squiers, John J.; Adamson, Douglas H.; Herrera-Alonso, Margarita; Wohl, Adam R.; Hoye, Thomas R.; Macosko, Christopher W.; Mayer, Lawrence D.; Vauthier, Christine; Prud'homme, Robert K.

Pharmacokinetics of CPX-351: A nano-scale liposomal fixed molar ratio of cytarabine-daunorubicin (Cyt:Daun) in patients with advanced leukemia

CANCER RESEARCH

IF16.6

2011-04-01

PREAI

Feldman, Eric J.; Lancet, Jeffrey E.; Kolitz, Jonathan E.; Trang, John M.; Mayer, Lawrence D.; Swenson, Chris E.; Chiarella, Michael T.; Louie, Arthur C.

Evaluation of CPX-351 (cytarabine:daunorubicin) liposome injection efficacy in acute lymphoblastic leukemia (ALL) xenograft models

MOLECULAR CANCER THERAPEUTICS

IF5.5

2009-12-01

PREAI

Mayer, Lawrence; Carol, Hernan; Morton, Christopher L.; Harasym, Troy; Smith, Malcolm A.; Lock, Richard B.

Drug ratio-dependent antitumor activity of irinotecan and cisplatin combinations in vitro and in vivo

MOLECULAR CANCER THERAPEUTICS

IF5.5

2009-08-14

123

OAAI

Tardi, Paul G.; Dos Santos, Nancy; Harasym, Troy O.; Johnstone, Sharon A.; Zisman, Natalia; Tsang, Alan W.; Bermudes, David G.; Mayer, Lawrence D.

Safety, Pharmacokinetics, and Efficacy of CPX-1 Liposome Injection in Patients with Advanced Solid Tumors

CLINICAL CANCER RESEARCH

IF10.2

2009-01-15

209

OAAI

Batist, Gerald; Gelmon, Karen A.; Chi, Kim N.; Miller, Wilson H., Jr.; Chia, Stephen K. L.; Mayer, Lawrence D.; Swenson, Christine E.; Janoff, Andrew S.; Louie, Arthur C.

Clinical and preclinical pharmacology of liposomal vincristine

JOURNAL OF LIPOSOME RESEARCH

IF4.3

2008-09-28

PREAI

Webb, MS; Sarris, AH; Cabanillas, F; Mayer, LD; Bally, MB; Burge, C; Cullis, PR

Designing liposomal anticancer drug formulations for specific therapeutic applications

JOURNAL OF LIPOSOME RESEARCH

IF4.3

2008-09-28

PREAI

Mayer, LD; Krishna, R; Webb, M; Bally, M

Liposomal anticancer drugs as agents to be used in combination with other anticancer agents: Studies on a liposomal formulation with two encapsulated drugs

JOURNAL OF LIPOSOME RESEARCH

IF4.3

2008-09-28

PREAI

Saxon, DN; Mayer, LD; Bally, MB

Controlling the drug delivery attributes of lipid-based drug formulations

JOURNAL OF LIPOSOME RESEARCH

IF4.3

2008-09-28

PREAI

Bally, MB; Lim, H; Cullis, PR; Mayer, LD

Modulating the therapeutic activity of nanoparticle delivered paclitaxel by manipulating the hydrophobicity of prodrug conjugates

JOURNAL OF MEDICINAL CHEMISTRY

IF6.8

2008-05-09

147

PREAI

Ansell, Steven M.; Johnstone, Sharon A.; Tardi, Paul G.; Lo, Lily; Xie, Sherwin; Shu, Yu; Harasym, Troy O.; Harasym, Natashia L.; Williams, Laura; Bermudes, David; Liboiron, Barry D.; Saad, Walid; Prud'homme, Robert K.; Mayer, Lawrence D.

Intra and inter-molecular interactions dictate the aggregation state of irinotecan co-encapsulated with floxuridine inside liposomes

PHARMACEUTICAL RESEARCH

IF4.3

2008-03-05

PREAI

Dicko, Awa; Frazier, April A.; Liboiron, Barry D.; Hinderliter, Anne; Ellena, Jeff F.; Xie, Xiaowei; Cho, Connie; Weber, Tom; Tardi, Paul G.; Cabral-Lilly, Donna; Cafiso, David S.; Mayer, Lawrence D.

Role of copper gluconate/triethanolamine in irinotecan encapsulation inside the liposomes

INTERNATIONAL JOURNAL OF PHARMACEUTICS

IF5.2

2007-06-01

PREAI

Dicko, Awa; Tardi, Paul; Xie, Xiaowei; Mayer, Lawrence

Ratiometric dosing of anticancer drug combinations: Controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice

MOLECULAR CANCER THERAPEUTICS

IF5.5

2006-08-04

338

OAAI

Mayer, Lawrence D.; Harasym, Troy O.; Tardi, Paul G.; Harasym, Natashia L.; Shew, Clifford R.; Johnstone, Sharon A.; Ramsay, Euan C.; Bally, Marcel B.; Janoff, Andrew S.

研究方向